Slide 1: Second Quarter 2024 Earnings
„ Second Quarter 2024 Earnings August 08, 2024
Slide 2: Forward-Looking Statements & Non-GAAP Financial Measures
Forward-Looking Statements & Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (a
Slide 3: Q2 2024 Results vs PYQ2
Q2 2024 Results vs PYQ2 (in millions) Q2 GAAP Q2 Non-GAAP INSTRUMENTS CONSUMABLES ACCELERATOR OTHER 2023 2024 2023 2024 Revenue Mix 7% 51% 29% 13% Revenue 31.0 34.4 31.0 34.4 Gross Margin $ 19.1 20.1 17.5 18.0 Gross Margin % 61.7% 58.3% 56.4% 52.3% Revenue Q2 2023 Q2 2024 7% Operating Expense 28.7 3
Slide 4: Scientific Validation Driving Adoption
Scientific Validation Driving Adoption Neurology Infectious Diseases Immunology & Oncology Others INSTRUMENTS PUBLICATIONS BIOMARKERS Placements Cumulative Cumulative # of units placed Cumulative 222 Number of Drug 205 2,979 559 563 1,004 Trial Projects 538 972 2,781 168 27.8 480 876 149 23.6 132 2,
Slide 5: Neurofilament Light (NfL), a Key Biomarker for Clinical Trials and Research
Neurofilament Light (NfL), a Key Biomarker for Clinical Trials and Research Accelerator Partnerships Important Research * • ANNEXON partnered with Quanterix’s • NfL and GFAP biomarkers promising for Accelerator Lab, testing NfL for their pivotal screening brain metastases in patients with Phase 3 tr
Slide 6: Multi-marker: the Next Phase of AD Testing
Multi-marker: the Next Phase of AD Testing Tomorrow: Multi-Marker Test for AD Today: Single Marker p-Tau 217 A better test, with an algorithm, and potential for differential diagnosis Accurate Actionable +90% Sensitivity 10.5% Intermediate vs. p-Tau 217 p-Tau 217tests launched or in immunoassays +90
Slide 7: SIMOA: A Result for Every Patient
SIMOA: A Result for Every Patient SIMOA Mass Spectrometry Chemiluminescence ALL 280 390 1000 patients 1000 patients 1000 patients patients receive patients with NO patients with NO a result1 result2 result3 While most p-Tau 217 tests can achieve high accuracy (e.g., AUC), the best clinical utility i
Slide 8: SIMOA: Best in class for monitoring early AD
SIMOA: Best in class for monitoring early AD SIMOA Mass Spectrometry Chemiluminescence A result in each stage Result only in later stage Result only in later stage Disease progression / Time Year 5 Receive result Receive result Receive result Limit of Detection of other tests Year 4 Receive result N
Slide 9: New Partnerships Building the Testing Infrastructure for Alzheimer's Disease
New Partnerships Building the Testing Infrastructure for Alzheimer's Disease Health systems Caring for approximately 5 million patients annually* in the US Labs and tests With broad scale and geographic reach Access Partners have access to Quanterix’s ‘092 patent 9 *Estimated based on both inpatient
Slide 10: 2024 Guidance
2024 Guidance Full Year Revenue FY 2024 revenue expected to be between $134 to $138 million and excludes revenue related to Lucent Diagnostics testing, which we expect to be immaterial in 2024. Gross Margin Estimated FY 2024 GAAP Gross Margin percentage to be 57-61% and Non-GAAP Gross Margin percent
Slide 11: Reconciliation of GAAP to Non-GAAP Financial Measures
Reconciliation of GAAP to Non-GAAP Financial Measures Quanterix Corporation Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited and in thousands, except percentages) Three Months Ended June 30, S ix Months Ended June 30, 2024 2023 2024 2023 GAAP gross profit $ 20,058
Slide 12: „
„